// App-Quantinova.ai

570 : A U.S. Food and Drug Administration (FDA) pooled analysis of outcomes for bone only metastatic breast cancer (MBC).

Researchers

Presenter

  • Suparna B. Wedam

Principal Investigators

  • Julia A. Beaver

  • Laleh Amiri-Kordestani

  • Erik Bloomquist

  • Shenghui Tang

  • Rajeshwari Sridhara

  • Amna Ibrahim

  • Geoffrey Kim

  • Paul Gustav Kluetz

  • Amy E. McKee

  • Richard Pazdur

Medical Centers

  • U.S. Food and Drug Administration, Silver Spring, MD

  • U.S. Food and Drug Administration, Bethesda, MD

  • FDA, Silver Spring, MD

  • U.S. Food and Drug Administration, Silver Spring, MD

  • U.S. Food and Drug Administration, Kensington, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Bone metastases

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

  • Prospective

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved